Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$166 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-37.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
207.7
Industry P/E
--
EV/EBITDA
-4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.6
Face value
--
Shares outstanding
64,472,792
CFO
$-191.67 Mln
EBITDA
$-229.82 Mln
Net Profit
$-235.52 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Galectin Therapeutics (GALT)
| -35.6 | -10.1 | -35.6 | 119.7 | 8.5 | 4.3 | 6.5 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Galectin Therapeutics (GALT)
| 222.5 | -22.1 | 46.9 | -45.4 | -7.6 | -21.7 | -16.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Galectin Therapeutics (GALT)
|
2.7 | 165.7 | 0.0 | -37.3 | -66,177.8 | -- | -- | 207.7 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 228.2 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3... inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Address: 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071 Read more
President, CEO & Director
Mr. Joel Lewis
CFO, Treasurer & Corporate Secretary
Mr. Jack W. Callicutt CPA
Headquarters
Norcross, GA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Galectin Therapeutics Inc (GALT) is $2.68 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Galectin Therapeutics Inc (GALT) has given a return of 8.47% in the last 3 years.
Since, TTM earnings of Galectin Therapeutics Inc (GALT) is negative, P/E ratio is not available.
The P/B ratio of Galectin Therapeutics Inc (GALT) is 207.70 times as on 31-Mar-2026, a 5172 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.72
|
-0.79
|
|
2023
|
-2.43
|
-1.66
|
|
2022
|
-1.73
|
-2.09
|
|
2021
|
-3.97
|
46.31
|
|
2020
|
-5.45
|
5.28
|
The 52-week high and low of Galectin Therapeutics Inc (GALT) are Rs 7.13 and Rs 1.12 as of 02-Apr-2026.
Galectin Therapeutics Inc (GALT) has a market capitalisation of $ 166 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Galectin Therapeutics Inc (GALT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.11
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.